Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
33%
Ph early_phase_1
1
17%
Ph phase_1
3
50%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (16.7%)
Phase 13 (50.0%)
Phase 22 (33.3%)

Trials by Status

withdrawn117%
completed467%
unknown117%

Recent Activity

0 active trials
Showing 5 of 6
withdrawnphase_2

Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation

NCT06214403
unknownphase_2

The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression

NCT04602715
completedphase_1

Safety and Efficacy of Microbial Ecosystem Therapeutic-2 (MET-2) in Patients With Ulcerative Colitis (UC)

NCT03832400
completedphase_1

The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression and/or Generalized Anxiety Disorder

NCT04052451
completedphase_1

MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)

NCT02865616
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06214403Phase 2

Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation

Withdrawn
NCT04602715Phase 2

The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression

Unknown
NCT03832400Phase 1

Safety and Efficacy of Microbial Ecosystem Therapeutic-2 (MET-2) in Patients With Ulcerative Colitis (UC)

Completed
NCT04052451Phase 1

The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression and/or Generalized Anxiety Disorder

Completed
NCT02865616Phase 1

MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)

Completed
NCT03660748Early Phase 1

Safety and Efficacy of MET-3 in Obese Human Subjects

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6